-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

Benzinga·10/30/2026 16:44:04
Listen to the news
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.